PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-313.81%
Negative net income growth while CRVO stands at 49.17%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
289.12%
SBC growth of 289.12% while CRVO is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
-122.10%
Negative yoy working capital usage while CRVO is 15704.74%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
113.90%
AP growth well above CRVO's 40.78%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-180.39%
Negative yoy usage while CRVO is 1829.01%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2618.61%
Some yoy increase while CRVO is negative at -144.71%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
17.02%
Operating cash flow growth below 50% of CRVO's 99.81%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-23.76%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.76%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-278.89%
Both yoy lines negative, with CRVO at -100.00%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.